News
Videos
Conferences
Events
Resources
Subscribe

|Videos|January 20, 2016

Pancreatic Cancer: Donald's Story

Episodes in this series

EP. 1 Treatment Options and Challenges for Patients With Pancreatic Cancer

EP. 1 Treatment Options and Challenges for Patients With Pancreatic Cancer

EP. 2 A Promising Future for Pancreatic Cancer

EP. 2 A Promising Future for Pancreatic Cancer

EP. 3 Pancreatic Cancer: David's Story to Remission

EP. 3 Pancreatic Cancer: David's Story to Remission

EP. 4 Pancreatic Cancer: Donald's Story

EP. 4 Pancreatic Cancer: Donald's Story

EP. 5 Locating Support Resources for Patients

EP. 5 Locating Support Resources for Patients

EP. 6 Treatment Considerations for Patients Researching Their Options

EP. 6 Treatment Considerations for Patients Researching Their Options

EP. 7 Moving Forward With Pancreatic Cancer

EP. 7 Moving Forward With Pancreatic Cancer

EP. 8 Receiving a Second Opinion

EP. 8 Receiving a Second Opinion

EP. 9 Maintenance Therapy: What to Expect

EP. 9 Maintenance Therapy: What to Expect

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Dr. Pablo Prichard

What MRD Testing Can Mean for Patients With Breast Cancer and Survivors

ByDr. Pablo Prichard

February 1st 2026

breast cancer

Ibrance Adds 15 Months of Progression-Free Survival in HR+, HER2+ Breast Cancer

January 30th 2026

Bonnie Annis

The Last Walk Down the Hall: Reflections Before Entering Cancer Survivorship

January 30th 2026

Dr. Brittany Dulmage explains how biotin can interfere with lab testing during cancer care: © The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

Biotin, Lab Interference and Safer Options for Cancer-Related Hair Loss

January 30th 2026

breast cancer

Study Identifies Why Some Breast Cancers Resist Enhertu Treatment

January 30th 2026

Trending on CURE

Most Patients With HER2+ Breast Cancer Miss Standard Treatment, Study Shows

Key GI Cancer Advances from the 2026 ASCO Symposium

Smoldering Multiple Myeloma: An Overview for Newly Diagnosed Patients

Ibrance Adds 15 Months of Progression-Free Survival in HR+, HER2+ Breast Cancer

Study Identifies Why Some Breast Cancers Resist Enhertu Treatment